Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Aranesp study

Executive Summary

National Cancer Institute study to identify equivalent doses of Aranesp and J&J's Procrit should not be necessary for CMS to revise its reimbursement decision on Amgen's anemia agent, company tells analysts April 22. Amgen, CMS have been involved in "a dense set of discussions...looking at large amounts of clinical data," CEO Kevin Sharer says. "We don't expect...that any trial run by another part of the government will be necessary to come to the right conclusion and...I don't think, at this point...that [CMS sees] that as necessary either," Sharer says. CMS contracted the NCI study when it decided Aranesp should be reimbursed at the same rate as Procrit (1"The Pink Sheet" Nov. 4, 2002, p. 27)...

You may also be interested in...



Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule

The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003

AAM Welcomes Proposal To Update Medicare Part D

After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel